An Open-label Multicentre, Follow-up Trial to Assess the Long-term Safety and Tolerability of Oral Administration of Talsaclidine 24 mg Tid in Patients With Mild to Moderate Dementia of the Alzheimer Type

Trial Profile

An Open-label Multicentre, Follow-up Trial to Assess the Long-term Safety and Tolerability of Oral Administration of Talsaclidine 24 mg Tid in Patients With Mild to Moderate Dementia of the Alzheimer Type

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 06 Oct 2014

At a glance

  • Drugs Talsaclidine (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 06 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top